NIH will fund seven-year trial of Proscar and Cardura for BPH; Hytrin outperforms Proscar in V-A study.

Executive Summary

NIH WILL FUND SEVEN-YEAR BPH DISEASE PROGRESSION THERAPY COMPARISON study with $50 mil. grant, Herbert Lepor, MD, New York University School of Medicine, said at a "Prostate Health Update" meeting in Washington, D.C. Aug. 25. The multicenter trial will randomize approximately 2,800 men to placebo, Pfizer's Cardura (doxazosin), Merck's Proscar (finasteride) and doxazosin in combination with finasteride. The study also is expected to provide important implications of the natural history of benign prostatic hyperplasia.